Total Funding
45
48
Total FundingVenture - Series Unknown raised
Growth Score
-10 pts
Heat Score
-3 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
33548
Imvax is a biotechnology company focused on the development of novel patient-specific vaccines and immunotherapy strategies.
D. Craig Hooper: Co-Founder and Chief Scientific Officer
Peter Corr: Co-FounderPast Role: Pfizer, Senior Vice President for Science and Technology
About the Company
Imvax is a biotechnology company focused on the development of novel patient-specific vaccines and immunotherapy strategies for the treatment of malignant gliomas and other cancers with unmet medical needs.
Its product, IGV-001, is an autologous tumor cell vaccine that delivers a multi-pronged response against tumor cells by leveraging the
patient’s immune system as a defense mechanism.
The company was incorporated in 2015 by David W. Andrews, Craig Hooper, Arthur W. Howe, and Peter B. Corr in Philadelphia, Pennsylvania.
